Claudia Fattuoni

Dr. Claudia Fattuoni

University of Cagliari
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
MLMarco Lucarini
Marco Lucarini
PPPamela Pedrielli
Pamela Pedrielli
GPGian Franco Pedulli
Gian Franco Pedulli
SCSalvatore Cabiddu
Salvatore Cabiddu
CFClaudia Fattuoni
Claudia Fattuoni

6 October 2014 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
Antonio NotoAntonio Noto
Antonio Noto
VFVassilios Fanos
Vassilios Fanos
LBLuigi Barberini
Luigi Barberini
DGDmitry Grapov
Dmitry Grapov
CFClaudia Fattuoni
Claudia Fattuoni
Ruggiero FrancavillaRuggiero Francavilla
Ruggiero Francavilla
A supervised multivariate model to classify the metabolome alterations between autistic spectrum disorders (ASD) patients and controls, siblings of autistic patients, has been realized and used to realize a network model of the ASD patients' metabolome. In our experiment we propose a quantification of urinary metabolites with the Mass Spectroscopy technique couple to Gas Chromatography. A multivariate model has been used to extrapolate the variables of importance for a network model of interaction between metabolites. In this way we are able to propose a network-based approach to ASD description. Children with autistic disease composing our studied population showed elevated concentration of several organic acids and sugars. Interactions among diet, intestinal flora and genes may explain such findings. Among them, the 3-(3-hydroxyphenyl)-3-hydroxypropanoic acid has been previously described as altered in autistic subjects. Other metabolites increased are 3,4-dihydroxybutyric acid, glycolic acid and glycine, cis-aconitic acid; phenylalanine, tyrosine, p-hydroxyphenylacetic acid, and homovanillic acid are all involved in the tyrosine pathway leading to neurotransmitter cathecolamine. GC-MS-based metabolomic analysis of the urinary metabolome suggests to have the required sensitivity and specificity to gain insight into ASD phenotypes and aid a personalized network-based medicine approach.

1 January 2018 in Placenta
Verified
Journal Article
Closed access
CFClaudia Fattuoni
Claudia Fattuoni
CMChiara Mandò
Chiara Mandò
FPFrancesco Palmas
Francesco Palmas
GAGaia Maria Anelli
Gaia Maria Anelli
CNChiara Novielli
Chiara Novielli
ICIrene Cetin
Irene Cetin

17 April 2015 in Molecules
Verified
Journal Article
Open access
PDF file
CFClaudia Fattuoni
Claudia Fattuoni
FPFrancesco Palmas
Francesco Palmas
Antonio NotoAntonio Noto
Antonio Noto
Vassilios FanosVassilios Fanos
Vassilios Fanos
LBLuigi Barberini
Luigi Barberini
Perinatal asphyxia is defined as an oxygen deprivation that occurs around the time of birth, and may be caused by several perinatal events. This medical condition affects some four million neonates worldwide per year, causing the death of one million subjects. In most cases, infants successfully recover from hypoxia episodes; however, some patients may develop HIE, leading to permanent neurological conditions or impairment of different organs and systems. Given its multifactor dependency, the timing, severity and outcome of this disease, mainly assessed through Sarnat staging, are of difficult evaluation. Moreover, although the latest newborn resuscitation guideline suggests the use of a 21% oxygen concentration or room air, such an approach is still under debate. Therefore, the pathological mechanism is still not clear and a golden standard treatment has yet to be defined. In this context, metabolomics, a new discipline that has described important perinatal issues over the last years, proved to be a useful tool for the monitoring, the assessment, and the identification of potential biomarkers associated with asphyxia events. This review covers metabolomics research on perinatal asphyxia condition, examining in detail the studies reported both on animal and human models.

23 November 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
Michele MussapMichele Mussap
Michele Mussap
MSMartina Siracusano
Martina Siracusano
Antonio NotoAntonio Noto
Antonio Noto
CFClaudia Fattuoni
Claudia Fattuoni
ARAssia Riccioni
Assia Riccioni
LMLuigi Mazzone
Luigi Mazzone
Autism diagnosis is moving from the identification of common inherited genetic variants to a systems biology approach. The aims of the study were to explore metabolic perturbations in autism, to investigate whether the severity of autism core symptoms may be associated with specific metabolic signatures; and to examine whether the urine metabolome discriminates severe from mild-to-moderate restricted, repetitive, and stereotyped behaviors. We enrolled 57 children aged 2–11 years; thirty-one with idiopathic autism and twenty-six neurotypical (NT), matched for age and ethnicity. The urine metabolome was investigated by gas chromatography-mass spectrometry (GC-MS). The urinary metabolome of autistic children was largely distinguishable from that of NT children; food selectivity induced further significant metabolic differences. Severe autism spectrum disorder core deficits were marked by high levels of metabolites resulting from diet, gut dysbiosis, oxidative stress, tryptophan metabolism, mitochondrial dysfunction. The hierarchical clustering algorithm generated two metabolic clusters in autistic children: 85–90% of children with mild-to-moderate abnormal behaviors fell in cluster II. Our results open up new perspectives for the more general understanding of the correlation between the clinical phenotype of autistic children and their urine metabolome. Adipic acid, palmitic acid, and 3-(3-hydroxyphenyl)-3-hydroxypropanoic acid can be proposed as candidate biomarkers of autism severity.

6 October 2014 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
PDF file
LBLuigi Barberini
Luigi Barberini
Antonio NotoAntonio Noto
Antonio Noto
CFClaudia Fattuoni
Claudia Fattuoni
DGDmitry Grapov
Dmitry Grapov
ACAndrea Casanova
Andrea Casanova
ADAngelica Dessì
Angelica Dessì
Objective: Metabolomics is a new “omics” platform aimed at high-throughput identification, quantification and characterization of small-molecule metabolites. The metabolomics approach has been successfully applied to the classification different physiological states and identification of perturbed biochemical pathways. The purpose of the current investigation is the application of metabolomics to explore biological mechanisms which may lead to the onset of metabolic syndrome in adulthood. Methods: We evaluated differences in metabolites in the urine collected within 12 h from 23 infants with IUGR (IntraUterine Growth Restriction), or LGA (Large for Gestational Age), compared to control infants (10 patients defined AGA: Appropriate for Gestational Age). Urinary metabolites were quantified by GC-MS and used to highlight similarities between the two metabolic diseases and identify metabolic markers for their predisposition. Quantified metabolites were analyzed using a multivariate statistics coupled with receiver operator characteristic curve (ROC) analysis of identified biomarkers. Results: Urinary myo-inositol was the most important discriminant between LGA + IUGR and control infants, and displayed an area under the ROC curve = 1. Conclusion: We postulate that the increase in plasma and consequently urinary inositol may constitute a marker of altered glucose metabolism during fetal development in both IUGR and LGA newborns.